Tags

Type your tag names separated by a space and hit enter

Hormone therapy and raloxifene reduce the coagulation inhibitor potential.
Blood Coagul Fibrinolysis. 2007 Jul; 18(5):455-60.BC

Abstract

The coagulation inhibitor potential (CIP) assay may detect major thrombophilia at a sensitivity of 100% and a specificity of 70-80%. Subnormal CIP might be associated with increased risk of thrombosis. This study compared the effect on CIP in plasma samples from postmenopausal women treated with four different regimens. Fibrin aggregation in plasma was monitored after activation with tissue factor. The effect of potentiated inhibition of coagulation was measured. Plasma samples from 202 healthy women randomly assigned to receive treatment for 12 weeks with conventional-dose or low-dose hormone therapy, raloxifene or tibolone were examined. Major thrombophilias were excluded. Compared with baseline, the median level in CIP was reduced by 64% in the conventional-dose group, by 38% in the low-dose group and by 31% in the raloxifene group, whereas for those treated with tibolone the median CIP increased by 9%. The median changes in CIP were significant for both hormone therapy groups (P < 0.0001) and for the raloxifene group (P = 0.003), but not for the tibolone group (P = 0.653). The 12 women with heterozygous factor V Leiden mutation had a significantly reduced median CIP level (P < 0.0001) at baseline. Hormone therapy and raloxifene, associated with venous thromboembolism, reduce the CIP. Tibolone does not reduce the CIP.

Authors+Show Affiliations

Haematological Research Laboratory, Department of Medicine, Aker University Hospital Trust, Oslo, Norway. marianneseierstad.andresen@akersykehus.noNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17581320

Citation

Andresen, Marianne S., et al. "Hormone Therapy and Raloxifene Reduce the Coagulation Inhibitor Potential." Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, vol. 18, no. 5, 2007, pp. 455-60.
Andresen MS, Eilertsen AL, Abildgaard U, et al. Hormone therapy and raloxifene reduce the coagulation inhibitor potential. Blood Coagul Fibrinolysis. 2007;18(5):455-60.
Andresen, M. S., Eilertsen, A. L., Abildgaard, U., & Sandset, P. M. (2007). Hormone therapy and raloxifene reduce the coagulation inhibitor potential. Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, 18(5), 455-60.
Andresen MS, et al. Hormone Therapy and Raloxifene Reduce the Coagulation Inhibitor Potential. Blood Coagul Fibrinolysis. 2007;18(5):455-60. PubMed PMID: 17581320.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormone therapy and raloxifene reduce the coagulation inhibitor potential. AU - Andresen,Marianne S, AU - Eilertsen,Anette L, AU - Abildgaard,Ulrich, AU - Sandset,Per Morten, PY - 2007/6/22/pubmed PY - 2007/12/28/medline PY - 2007/6/22/entrez SP - 455 EP - 60 JF - Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis JO - Blood Coagul. Fibrinolysis VL - 18 IS - 5 N2 - The coagulation inhibitor potential (CIP) assay may detect major thrombophilia at a sensitivity of 100% and a specificity of 70-80%. Subnormal CIP might be associated with increased risk of thrombosis. This study compared the effect on CIP in plasma samples from postmenopausal women treated with four different regimens. Fibrin aggregation in plasma was monitored after activation with tissue factor. The effect of potentiated inhibition of coagulation was measured. Plasma samples from 202 healthy women randomly assigned to receive treatment for 12 weeks with conventional-dose or low-dose hormone therapy, raloxifene or tibolone were examined. Major thrombophilias were excluded. Compared with baseline, the median level in CIP was reduced by 64% in the conventional-dose group, by 38% in the low-dose group and by 31% in the raloxifene group, whereas for those treated with tibolone the median CIP increased by 9%. The median changes in CIP were significant for both hormone therapy groups (P < 0.0001) and for the raloxifene group (P = 0.003), but not for the tibolone group (P = 0.653). The 12 women with heterozygous factor V Leiden mutation had a significantly reduced median CIP level (P < 0.0001) at baseline. Hormone therapy and raloxifene, associated with venous thromboembolism, reduce the CIP. Tibolone does not reduce the CIP. SN - 0957-5235 UR - https://www.unboundmedicine.com/medline/citation/17581320/Hormone_therapy_and_raloxifene_reduce_the_coagulation_inhibitor_potential_ L2 - http://dx.doi.org/10.1097/MBC.0b013e32813a2de7 DB - PRIME DP - Unbound Medicine ER -